Company: CWAN
Filing Date: 2025-03-06
Form Type: S-4/A
Source: 0001193125-25-048570
Chunk: 207

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-06
Form: S-4/A
Chunk 207
---
 capital stock or voting securities of Enfusion, (iii) subscriptions, options, warrants or other rights or arrangements to acquire from Enfusion, or other obligations or commitments of Enfusion to issue, any capital stock or other voting securities or ownership interests in, or any securities convertible into or exchangeable for capital stock or other voting securities or ownership interests in, Enfusion, (iv) restricted shares, stock appreciation rights, performance shares, contingent value rights, profits interests, equity-based or “phantom” stock or similar securities or rights that are derivative of, or provide economic benefits based, directly or indirectly, on the value or price of, any capital stock of, or other voting securities or ownership interests in, Enfusion. “ Enfusion Stock Option” means each option to purchase shares of Enfusion Common Stock and Enfusion Class B Common Stock granted under the Enfusion Stock Plan. “ Enfusion Stock Plan” means the 2021 Stock Options and Incentive Plan, as amended, restated, supplemented or otherwise modified from time to time in accordance with its terms. “ ERISA” means the Employee Retirement Income Security Act of 1974 and the rules and regulations promulgated thereunder. “ Foreign Employee Plan” means any Enfusion Employee Plan that is maintained pursuant to or is subject to the laws of a country other than the United States, or provides compensation or benefits to participants providing services primarily outside of the United States. Covenants of Enfusion Prior to Completion of the Transactions The Merger Agreement provides that, except for matters (i) required, expressly permitted or expressly contemplated by the Merger Agreement, (ii) set forth in Enfusion’s confidential disclosure schedules to the Merger Agreement (the “ Enfusion Disclosure Schedules”), (iii) required by applicable law or (iv) undertaken with the prior written consent of Clearwater (which consent will not be unreasonably withheld, conditioned or delayed and provided that the failure of Clearwater to respond to a request in writing for consent within five business days after receipt thereof will be deemed to constitute consent), Enfusion will, and will cause each of its subsidiaries to:

| • |     | use commercially reasonable efforts to conduct its business in the ordinary course; and |

| • |     | use commercially reasonable efforts to preserve the present business operations, organization and goodwill of                                                                                                                                           
 Enfusion and its subsidiaries, including using commercially reasonable efforts to retain the services of key employees of Enfusion and its subsidiaries and preserve their relationships with, and the goodwill of, clients,